CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 1.81 HKD -0.55% Market Closed
Market Cap: 2.3B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

Intrinsic Value

The intrinsic value of one CStone Pharmaceuticals stock under the Base Case scenario is 3.25 HKD. Compared to the current market price of 1.81 HKD, CStone Pharmaceuticals is Undervalued by 44%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
3.25 HKD
Undervaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
CStone Pharmaceuticals

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CStone Pharmaceuticals cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CStone Pharmaceuticals?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about CStone Pharmaceuticals

Provide an overview of the primary business activities
of CStone Pharmaceuticals.

What unique competitive advantages
does CStone Pharmaceuticals hold over its rivals?

What risks and challenges
does CStone Pharmaceuticals face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CStone Pharmaceuticals.

Provide P/S
for CStone Pharmaceuticals.

Provide P/E
for CStone Pharmaceuticals.

Provide P/OCF
for CStone Pharmaceuticals.

Provide P/FCFE
for CStone Pharmaceuticals.

Provide P/B
for CStone Pharmaceuticals.

Provide EV/S
for CStone Pharmaceuticals.

Provide EV/GP
for CStone Pharmaceuticals.

Provide EV/EBITDA
for CStone Pharmaceuticals.

Provide EV/EBIT
for CStone Pharmaceuticals.

Provide EV/OCF
for CStone Pharmaceuticals.

Provide EV/FCFF
for CStone Pharmaceuticals.

Provide EV/IC
for CStone Pharmaceuticals.

Show me price targets
for CStone Pharmaceuticals made by professional analysts.

What are the Revenue projections
for CStone Pharmaceuticals?

How accurate were the past Revenue estimates
for CStone Pharmaceuticals?

What are the Net Income projections
for CStone Pharmaceuticals?

How accurate were the past Net Income estimates
for CStone Pharmaceuticals?

What are the EPS projections
for CStone Pharmaceuticals?

How accurate were the past EPS estimates
for CStone Pharmaceuticals?

What are the EBIT projections
for CStone Pharmaceuticals?

How accurate were the past EBIT estimates
for CStone Pharmaceuticals?

Compare the revenue forecasts
for CStone Pharmaceuticals with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CStone Pharmaceuticals and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CStone Pharmaceuticals against its competitors.

Analyze the profit margins
(gross, operating, and net) of CStone Pharmaceuticals compared to its peers.

Compare the P/E ratios
of CStone Pharmaceuticals against its peers.

Discuss the investment returns and shareholder value creation
comparing CStone Pharmaceuticals with its peers.

Analyze the financial leverage
of CStone Pharmaceuticals compared to its main competitors.

Show all profitability ratios
for CStone Pharmaceuticals.

Provide ROE
for CStone Pharmaceuticals.

Provide ROA
for CStone Pharmaceuticals.

Provide ROIC
for CStone Pharmaceuticals.

Provide ROCE
for CStone Pharmaceuticals.

Provide Gross Margin
for CStone Pharmaceuticals.

Provide Operating Margin
for CStone Pharmaceuticals.

Provide Net Margin
for CStone Pharmaceuticals.

Provide FCF Margin
for CStone Pharmaceuticals.

Show all solvency ratios
for CStone Pharmaceuticals.

Provide D/E Ratio
for CStone Pharmaceuticals.

Provide D/A Ratio
for CStone Pharmaceuticals.

Provide Interest Coverage Ratio
for CStone Pharmaceuticals.

Provide Altman Z-Score Ratio
for CStone Pharmaceuticals.

Provide Quick Ratio
for CStone Pharmaceuticals.

Provide Current Ratio
for CStone Pharmaceuticals.

Provide Cash Ratio
for CStone Pharmaceuticals.

What is the historical Revenue growth
over the last 5 years for CStone Pharmaceuticals?

What is the historical Net Income growth
over the last 5 years for CStone Pharmaceuticals?

What is the current Free Cash Flow
of CStone Pharmaceuticals?

Discuss the annual earnings per share (EPS)
trend over the past five years for CStone Pharmaceuticals.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CStone Pharmaceuticals

Current Assets 1.3B
Cash & Short-Term Investments 1B
Receivables 172.4m
Other Current Assets 130.7m
Non-Current Assets 332.2m
Long-Term Investments 3.5m
PP&E 153.4m
Intangibles 173m
Other Non-Current Assets 2.3m
Current Liabilities 850.3m
Accounts Payable 246.4m
Accrued Liabilities 389.9m
Other Current Liabilities 214m
Non-Current Liabilities 354.8m
Long-Term Debt 224.1m
Other Non-Current Liabilities 130.7m
Efficiency

Earnings Waterfall
CStone Pharmaceuticals

Revenue
456.5m CNY
Cost of Revenue
-133.6m CNY
Gross Profit
322.9m CNY
Operating Expenses
-620.1m CNY
Operating Income
-297.2m CNY
Other Expenses
154.9m CNY
Net Income
-142.3m CNY

Free Cash Flow Analysis
CStone Pharmaceuticals

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

CStone Pharmaceuticals's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

25/100
Profitability
Score

CStone Pharmaceuticals's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

CStone Pharmaceuticals's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
41/100
Solvency
Score

CStone Pharmaceuticals's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
CStone Pharmaceuticals

Wall Street analysts forecast CStone Pharmaceuticals stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CStone Pharmaceuticals is 2.56 HKD with a low forecast of 2.54 HKD and a high forecast of 2.64 HKD.

Lowest
Price Target
2.54 HKD
40% Upside
Average
Price Target
2.56 HKD
41% Upside
Highest
Price Target
2.64 HKD
46% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CStone Pharmaceuticals?

Click here to dive deeper.

Dividends

CStone Pharmaceuticals
does not pay dividends
Shareholder Yield

Current shareholder yield for CStone Pharmaceuticals is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

CStone Pharmaceuticals Logo
CStone Pharmaceuticals

Country

China

Industry

Biotechnology

Market Cap

2.3B HKD

Dividend Yield

0%

Description

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Contact

SHANGHAI
Shanghai
11th Floor, Qiushi Building, No. 383 Guangyan Road, Jing'an District
www.cstonepharma.com

IPO

2019-02-26

Employees

264

Officers

CEO, President of R&D and Executive Director
Dr. Jianxin Yang M.D., Ph.D.
CFO & Joint Company Secretary
Ms. Weicong Ni
Senior VP & Chief Operating Officer
Ms. Ying Hua Zhang
Senior VP & Chief Scientific Officer
Dr. Ngai Chiu Tse M.D., Ph.D.
Chief Commercial & Strategic Officer
Mr. Michael J. Choi M.B.A.
Senior Vice President of Product Development
Dr. Yujuan La
Show More
Joint Company Secretary
Ms. Mei Yee Yung FCIS, FCS
Show Less

See Also

Discover More
What is the Intrinsic Value of one CStone Pharmaceuticals stock?

The intrinsic value of one CStone Pharmaceuticals stock under the Base Case scenario is 3.25 HKD.

Is CStone Pharmaceuticals stock undervalued or overvalued?

Compared to the current market price of 1.81 HKD, CStone Pharmaceuticals is Undervalued by 44%.

Back to Top